Ipamorelin

This peptide is offered in two variations: 2mg and 5mg.

Our Ipamorelin for sale is a pentapeptide, which displays high GH releasing potency and efficacy in vitro and in vivo. Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of Ipamorelin makes this compound a very interesting candidate for future clinical development.

Ipamorelin is a research peptide that stimulates the release of growth hormone (GH). It is composed of five amino acids and is thus known as a pentapeptide. Ipamorelin is often lumped together with CJC 1295, though they are two different compounds.

Ipamorelin was originally developed by Novo Nordisk Inc. It was investigated in phase 2 trials as a treatment for postoperative ileus, a condition in which the bowel stops functioning after surgical procedures. However, due to lack of efficacy, it was discontinued.

Pharmacological profiling using growth hormone-releasing peptide (GHRP) and growth-hormone-releasing hormone (GHRH) antagonists has clearly demonstrated that Ipamorelin stimulates GH release via a GH-like receptor. Its selectivity for GH is similar to that displayed by GHRH.